PŘEHLEDOVÉ ČLÁNKY Duální GIP a GLP-1 agonisté a změny lipidového spektra | 39 / Vnitř Lék. 2024;70(1):35-39 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 12. Berberich AJ, Hegele RA. Lipid effects of glucagon-like peptide 1 receptor analogs. Curr Opin Lipidol. 2021;32:191-199. 13. Dahl K, Brooks A, Almazedi F, et al. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23:1594-1603. 14. Novodvorský P, Haluzík M. The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia. Curr Atheroscler Rep. 2022;24:13-21. 15. Mulvihill EE. Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. Curr Opin Lipidol. 2018;29:95-103. 16. Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21:169. 17. Moura FA, Scirica BM, Ruff CT. Tirzepatide for diabetes: on track to SURPASS current therapy. Nat Med. 2022;28:450-451. 18. https://clinicaltrials.gov/ct2/show/NCT04255433. 19. Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28:591-598. 20. Wilson JM, Nikooienejad A, Robins DA, et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22:2451-2459. 21. Várkonyi TT, Pósa A, Pávó N, et al. Perspectives on weight control in diabetes - Tirzepatide. Diabetes Res Clin Pract. 2023;202:110770. 22. Nauck MA, Quast DR, Wefers J, et al. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab. 2021;23(Suppl 3):5-29. 23. Wilson JM, Lin Y, Luo MJ, et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis. Diabetes Obes Metab. 2022;24:148-153. 24. Tschöp M, Nogueiras R, Ahrén B. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023;66:1796-1808. 25. Tan TM. Co-agonist therapeutics come of age for obesity. Nat Rev Endocrinol. 2023;19:66-67. 26. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active- -controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402:529-544. 27. Jastreboff AM, Kaplan LM, Frías JP, et al. Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389:514-526. 28. Abdelmalek MF, Suzuki A, Sanchez W, et al. A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy- -confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study. Contemp Clin Trials. 2023; doi: 10.1016/j.cct.2023.107176. ODBORNÝ GARANT: prof. MUDr. Michal Vrablík, Ph.D. III. interní klinika 1. LF UK a VFN v Praze POŘADATEL: SOLEN, s. r. o. PARTNER POČET KREDITŮ 2 Registrace ZDARMA TERMÍN září 2023 až srpen 2024 dostupný na online.solen.cz On-line kurz Kardiologie ON LINE KURZ PŘEDNÁŠKY Co je u nových tabulek SCORE opravdu důležité? Modelové situace v ordinaci a jak je řešit – MUDr. Jaromír Ožana, MUDr. Michal Mačák Speciality v léčbě hypertenze – doc. MUDr. Ondřej Petrák, Ph.D. Aktuality a praktické tipy v léčbě dyslipidemie – MUDr. Eva Tůmová, Ph.D. Co (ne)budeme potřebovat od biochemické laboratoře pro stanovení kardiovaskulárního rizika? – prof. MUDr. Michal Vrablík, Ph.D.
RkJQdWJsaXNoZXIy NDA4Mjc=